This funding opportunity accelerates the translation of NIH-supported biomarker assays into clinical use by supporting the adaptation and clinical validation of molecular, cellular, and imaging markers for cancer detection, diagnosis, prognosis, monitoring, and treatment response prediction. It supports acquisition of well-annotated specimens and encourages multidisciplinary collaboration among scientists, clinicians, statisticians, and clinical laboratory staff. Early-stage technology development and clinical trials are excluded.
Eligible applicants include a wide range of organizations such as nonprofits, government entities, educational institutions, tribal organizations, small businesses, and foreign organizations. Specific eligibility details include various federally recognized and non-recognized tribal entities, faith-
